This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, trial data show that first‐line pirtobrutinib significantly improves progression‐free survival in patients with previously untreated chronic or small lymphocytic leukemia. In addition, the FDA approves perioperative pembrolizumab plus enfortumab vedotin for cisplatin‐ineligible muscle‐invasive bladder cancer, and a trial shows that risk‐based breast cancer screening is noninferior to annual screening.
Leah Lawrence (Wed,) studied this question.